Article Text

PDF
Original article
Intravitreal bevacizumab for retinal vein occlusion and early growth of epiretinal membrane: a possible secondary effect?
  1. Joaquin Marticorena1,
  2. Mario R Romano2,
  3. Heinrich Heimann2,
  4. Theodore Stappler2,
  5. Kurshid Gibran3,
  6. Carl Groenewald2,
  7. Ian Pearce2,
  8. David Wong4
  1. 1Instituto Tecnológico de Oftalmología, Santiago de Compostela, Spain
  2. 2Saint Paul's Eye Unit. Royal Liverpool University Hospital, Liverpool, UK
  3. 3Department of Ophthalmology, UTMB, Galveston, Texas, USA
  4. 4Faculty of Medicine Li Ka Shing, University of Hong Kong, Hong Kong SAR, China
  1. Correspondence to Dr Joaquin Marticorena, Instituto Tecnológico de Oftalmología, Hospital Nuestra Señora de la Esperanza, Av de las Burgas 2, Santiago de Compostela, Spain; jmarticorena{at}gmail.com

Abstract

Aims To report the early development of epiretinal membranes (ERM) in eyes with retinal vein occlusions (RVO) treated with intravitreal bevacizumab and to describe possible mechanisms that may be involved in the growth and contraction of these lesions.

Methods Retrospective and interventional study that included 25 eyes of 25 patients with RVO (16 eyes with central retinal vein occlusion and nine eyes with branch retinal vein occlusion). After an initial 2.5 mg/0.1 ml intravitreal bevacizumab injection all patients were followed-up every 6 weeks. Re-treatments were based on visual acuity and optical coherence tomography findings.

Results Twenty-five eyes were treated with bevacizumab and followed for 8.3 (range 4.5–13.5) months. Four eyes developed an ERM within 6–7 weeks after the administration of bevacizumab. ERM was not associated with further deterioration of visual acuity or metamorphopsia in these patients. A rebound of macular oedema was observed in one patient with ERM and in two other patients. No other side effects were observed.

Conclusions Intravitreal bevacizumab may be associated with an early growth of ERM in eyes with RVO, although a causative relationship cannot be established. Future randomised clinical trials are necessary to determine the efficacy and safety profile of this novel therapy.

  • Vein occlusion
  • epiretinal membrane
  • ischaemia
  • retina
  • macula
  • drugs

Statistics from Altmetric.com

Footnotes

  • Competing interests None.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Ethics Committee of the Royal Liverpool University Hospital, Liverpool, UK.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • At a glance
    Harminder S Dua Arun D Singh